Skip to main content

SELLAS Life Sciences Group, Inc.

corporate_fare Company Profile

SELLAS Life Sciences Group, Inc.

SLS·NASDAQ·Life Sciences·CIK 0001390478

We are a late-stage clinical biopharmaceutical company focused on developing new treatments for various cancer types. Our main product candidates are galinpepimut-S (GPS) and SLS009 (tambiciclib). GPS is a peptide immunotherapy targeting the Wilms tumor 1 (WT1) antigen, licensed from Memorial Sloan Kettering Cancer Center. The WT1 protein is found in 20 or more cancer types. GPS is designed to work as a standalone treatment or in combination with other immunotherapies for blood cancers and solid tumors. We are conducting an open-label, randomized Phase 3 clinical trial, called the REGAL study, for GPS as a monotherapy. This study involves patients with acute myeloid leukemia (AML) in the maintenance setting after achieving second complete remission (CR2) following second-line antileukemic therapy. Patients are randomly assigned to receive either GPS or best available treatment (BAT). The REGAL study's primary goal is to measure overall survival (OS). We planned to enroll approximately 125 to 140 patients across about 95 clinical sites in North America, Europe, and Asia. An interim analysis for safety, efficacy, and futility was planned after 60 events (deaths). Enrollment for the study was completed in March 2024. In December 2024, the pre-specified threshold of 60 events (deaths) was reached, initiating the interim analysis by the Independent Data Monitoring Committee (IDMC). In January 2025, the IDMC completed its interim analysis and recommended that the study continue without changes. Our second product candidate, SLS009 (tambiciclib), is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for SLS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 10 rated 8 or above. Recent SEC coverage for SLS spans 10-Q, 8-K.

Recent high-impact activity:

  • Sellas Prices $150M Offering at $13, a 28% Discount to Tuesday's Close
  • Cancer Vaccine Data Sends Shares Up 156%, Then $150M Offering Cools the Rally
  • $150M Equity Offering Launched Days After REGAL Trial Win
  • SELLAS Triples as Cancer Vaccine Cuts Death Risk 41% in Phase 3 Leukemia Trial
  • Phase 3 REGAL Win: Cancer Vaccine Cuts Death Risk 41% in AML, Median Survival 24.0 vs 14.7 Months

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$26.86M
Diluted EPS
-$0.25
Op. Cash Flow
-$28.39M
Operating Income
-$28.27M
Cash & Equivalents
$71.79M
Debt / Equity
0.00×
Shares Outstanding
153.1M sh
Source: 10-K · filed 2026-03-19 · accession 0001390478-26-000003

Short Interest & Short Volume

6.70 days to cover

FINRA reported short interest of 57,126,298 shares in SLS as of the October 30, 2026 settlement, a 6.3% increase from the prior period — about 6.7 days to cover at its recent average daily volume. On November 20, 2026, 57.1% of SLS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)57,126,298 shares as of October 30, 2026
Change vs prior period▲ 6.3%
Days to cover6.70 at avg daily volume of 8,528,857
Daily short volume (FINRA facilities)57.1% of 6,553,495 shares on November 20, 2026
5-day average short volume56.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for SLS, detected from its recent SEC filings · based on capital-structure filings through 2026-11-19.

1 recent capital raise

Final Terms of $150M Offering · Net Proceeds and Fees

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$14.21 +4.03% today
52-week range · as of 2026-11-12 $1.39 – $15.88
Market cap
$2.78B
Volume
15.5M (1.2× avg)
3-mo avg 13.4M
Live data · 2026-11-22 01:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SLS - Latest Insights

SLS
Nov 18, 2026, 10:00 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $17.98
Real-time Price: $14.21 info
Change: -$3.77 (-21%) info
Market Cap: $2.785B info
SLS
Nov 18, 2026, 12:03 AM EST
Source: CNBC TV18
Importance Score:
7
Price at Filing: $17.14
Real-time Price: $14.21 info
Change: -$2.93 (-17%) info
Market Cap: $2.785B info
SLS
Nov 17, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.03
Real-time Price: $14.21 info
Change: -$3.82 (-21%) info
Market Cap: $2.785B info
SLS
Nov 17, 2026, 10:09 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $20.45
Real-time Price: $14.21 info
Change: -$6.24 (-31%) info
Market Cap: $2.785B info
SLS
Nov 17, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
10
Price at Filing: $8.00
Real-time Price: $14.21 info
Change: +$6.21 (+78%) info
Market Cap: $2.785B info
SLS
Nov 12, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.01
Real-time Price: $14.21 info
Change: +$6.21 (+78%) info
Market Cap: $2.785B info
SLS
Oct 28, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $12.75
Real-time Price: $14.21 info
Change: +$1.46 (+11%) info
Market Cap: $2.785B info
SLS
Oct 01, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $12.36
Real-time Price: $14.21 info
Change: +$1.85 (+15%) info
Market Cap: $2.785B info
SLS
Aug 11, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $10.98
Real-time Price: $14.21 info
Change: +$3.24 (+29%) info
Market Cap: $2.785B info
SLS
Aug 11, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.97
Real-time Price: $14.21 info
Change: +$3.24 (+30%) info
Market Cap: $2.785B info
SLS
Aug 11, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.13
Real-time Price: $14.21 info
Change: +$3.08 (+28%) info
Market Cap: $2.785B info
SLS
Jul 27, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.88
Real-time Price: $14.21 info
Change: +$3.33 (+31%) info
Market Cap: $2.785B info
SLS
Jul 20, 2026, 7:21 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $13.61
Real-time Price: $14.21 info
Change: +$0.600 (+4%) info
Market Cap: $2.785B info
SLS
Jun 25, 2026, 8:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.17
Real-time Price: $14.21 info
Change: +$5.04 (+55%) info
Market Cap: $2.785B info
SLS
Jun 25, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.14
Real-time Price: $14.21 info
Change: +$5.07 (+55%) info
Market Cap: $2.785B info
SLS
Jun 18, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.16
Real-time Price: $14.21 info
Change: +$6.05 (+74%) info
Market Cap: $2.785B info
SLS
Jun 02, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.08
Real-time Price: $14.21 info
Change: +$5.13 (+56%) info
Market Cap: $2.785B info
SLS
May 27, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $8.18
Real-time Price: $14.21 info
Change: +$6.03 (+74%) info
Market Cap: $2.785B info
SLS
May 12, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.74
Real-time Price: $14.21 info
Change: +$8.47 (+148%) info
Market Cap: $2.785B info
SLS
May 12, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $5.22
Real-time Price: $14.21 info
Change: +$8.99 (+172%) info
Market Cap: $2.785B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets